The effects of bortezomib on bone disease in patients with multiple myeloma-Reference-Cited by-同舟云学术

The effects of bortezomib on bone disease in patients with multiple myeloma

Published:2013-11-18 Issue:5 Volume:120 Page:618-623
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Mohty Mohamad¹²³,Malard Florent²⁴,Mohty Bilal⁵,Savani Bipin⁶,Moreau Philippe⁴,Terpos Evangelos⁷

Affiliation:

1. Hematology Department; Saint-Antoine Hospital; Paris France

2. INSERM (National Institute of Health and Medical Research) 938; Paris France

3. Pierre and Marie Curie University; Paris France

4. Hematology Department; Nantes University Medical Center; Nantes France

5. Transplantation and Cellular Therapy Unit; Paoli-Calmettes Institute; Marseille France

6. Hematology and Stem Cell Transplantation Section; Division of Hematology/Oncology; Department of Medicine; Vanderbilt University Medical Center and Veterans Affairs Medical Center; Nashville Tennessee

7. Department of Clinical Therapeutics; University of Athens School of Medicine; Athens Greece

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference54 articles.

1. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression;Orlowski;J Clin Oncol.,2007

2. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial;Richardson;Blood.,2007

3. Velcade, intravenous cyclophosphamide and dexamethasone (VCD) induction for previously untreated multiple myeloma (German DSMM XIa Trial);Einsele;ASH Annual Meeting Abstracts,2009

4. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study;Cavo;Lancet.,2010

5. Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial;Mateos;Lancet Oncol.,2010

Cited by 48 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The role of E3 ubiquitin ligases in bone homeostasis and related diseases;Acta Pharmaceutica Sinica B;2023-10

2. Preventing osteolytic lesions and osteomyelitis in multiple myeloma;Journal of Bone Oncology;2022-12

3. Osteoimmunology: an interdisciplinary approach to studying the relationships between immune and bone cells;Medical Immunology (Russia);2022-10-31

4. Daratumumab Improves Bone Turnover in Relapsed/Refractory Multiple Myeloma; Phase 2 Study “REBUILD”;Cancers;2022-06-02

5. Trifluoperazine Synergistically Potentiates Bortezomib-Induced Anti-Cancer Effect in Multiple Myeloma via Inhibiting P38 MAPK/NUPR1;The Tohoku Journal of Experimental Medicine;2022